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Abstract
Background: The different isoforms of vascular endothelial growth factor (VEGF) play diverse
roles in vascular growth, structure and function. Alternative splicing of the VEGF gene results in
the expression of three abundant isoforms: VEGF121, VEGF165 and VEGF189. The mRNA for
VEGF189 contains the alternatively spliced exon 6A whereas the mRNA for VEGF165 lacks this
exon. The objective of this study was to identify the cis elements that control utilization of exon
6A. A reporter minigene was constructed (pGFP-E6A) containing the coding sequence for GFP
whose translation was dependent on faithful splicing for removal of the VEGF exon 6A. To identify
cis-acting splicing elements, sequential deletions were made across exon 6A in the pGFP-E6A
plasmid.
Results: A candidate cis-acting exonic splicing silencer (ESS) comprising nucleotides 22-30 of exon
6A sequence was identified corresponding to the a silencer consensus sequence of AAGGGG. The
function of this sequence as an ESS was confirmed in vivo both in the context of the reporter
minigene as a plasmid and in the context of a longer minigene with VEGF exon 6A in its native
context in an adenoviral gene transfer vector. Further mutagenesis studies resulted in the
identification of the second G residue of the putative ESS as the most critical for function.
Conclusion: This work establishes the identity of cis sequences that regulate alternative VEGF
splicing and dictate the relative expression levels of VEGF isoforms.
Background
Angiogenesis is a critical component of many physiologi-
cal and pathological processes such as tissue repair and
tumor growth. VEGF is the most powerful angiogenic fac-
tor mediating developmental, physiological and patho-
logical angiogenesis [1-3]. VEGF gene expression is a
complex process with regulation at the level of transcrip-
tion, mRNA stability and translation [4-10]. Through
alternate splicing, at least eight different isoforms of VEGF
are formed, comprising VEGF206, 189, 183, 165, 148,
145, 121, and an inhibitory isoforms, 165b [11-13]. Some
isoforms such as VEGF183 and 206 are expressed in a cell
and tissue restricted manner and the mechanisms by
which they are selectively spliced is unknown [14-16]. But
among the isoforms, VEGF189, 165 and 121 are the most
abundant in most tissues [17,18]. VEGF189 mRNA is rel-
atively abundant in mouse lung and heart, but VEGF165
mRNA has the highest level of expression in most other
mouse tissues [17-20]. These two isoforms differ by the
presence or absence of exon 6A which encodes the critical
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amino acids that confer differences in biological proper-
ties between VEGF165 andVEGF189 [11,20]. The utiliza-
tion of exon 6A presumably involves many factors such as
cis-acting RNA sequences within the exons and flanking
introns, and interactions with components of the basal
and alternate splicing machinery and auxiliary regulatory
factors which transiently co-assemble with the spliceo-
some.
The biological characteristics of the different VEGF iso-
forms are strikingly different with VEGF121 being soluble
but the longer isoforms, especially VEGF189, binding to
heparan in the extracellular matrix at the locations where
it is synthesized [20]. Cleavage of matrix associated
VEGF189 by proteases such as plasmin is critical for its
biological activity [20]. VEGF isoforms have different
affinities for the VEGF receptors [VEGFR1 (flt1), VEGFR2
(KDR/flk1) and VEGFR3 (neuropilin)] and may play dis-
tinct roles in vascular development and diseases such as
cancer growth and metastasis [19,21,22]. VEGF165 is able
to bind to VEGFR1, VEGFR2 as well as neuropilin-1;
VEGF121 binds to VEGFR1 and VEGFR2, but not neuropi-
lin-1, and VEGF189 binds to VEGFR1 in its native form
and binds to both VEGFR1 and VEGFR2 in its cleaved
form [3,23]. In general, studies on tumors which overex-
press VEGF121, VEGF165 or VEGF189 show that the
longer isoforms, especially VEGF189 or the mouse equiv-
alent VEGF188, are more effective in supporting tumor
growth and establishing xenografts [24-26]. The enhanced
in vivo growth of tumors expressing VEGF189 can be
partly explained by the cell-associated features of
VEGF189 and its high potential for induction of local ang-
iogenesis and tumor growth in cancer inductive microen-
vironments [27]. The different biologic characteristics of
the VEGF isoforms are also relevant to VEGF-mediated
therapeutic angiogenesis to treat disorders such as coro-
nary artery disease or peripheral vascular disease. In our
studies of angiogenic gene transfer, we discovered that
simultaneous expression of multiple VEGF isoforms
resulted in a more potent angiogenic signal than a single
isoform, presumably due to the overlapping biochemical
characteristics [28]. Other studies showed that over-
expression of VEGF189 provided a more favorable safety
profile than VEGF165 [29,30].
Based on these considerations, the objective of this study
was to test the hypothesis that cis sequences can be iden-
tified within the VEGF exon6A that control utilization of
exon 6A and promote or suppress production of
VEGF189. Using a reporter gene and in vitro gene transfer
assays, a cis acting element within exon 6A that signifi-
cantly affected the balance between VEGF189 and
VEGF165 was identified. Deletion and point mutations in
a putative exonic splicing silencer were created that mark-
edly enhanced the utilization of exon6A in vitro. These
mutations were then moved back into the context of the
VEGF gene and shown to have a similar effect on the splic-
ing of the VEGF gene, providing a basis for better under-
standing VEGF splicing and cell-specific expression of
VEGF isoforms.
Results
Generation of GFP Reporter Minigene
A minigene reporter system, pGFP-E6A, was developed in
which the splicing of the human VEGF exon 6A could
readily be monitored. The minigene consisted of a GFP
expression plasmid in which the GFP gene sequence was
interrupted by a shortened version of intron 5, the com-
plete exon 6A and a shortened version of intron 6 all from
the human VEGF gene (Figure 1). Upon transcription,
there could be two possible splicing events. If the splicing
pathway corresponds to that of VEGF189, exon 6A will be
included in the final mRNA and the GFP open reading
Splicing of endogenous VEGF gene and design of GFP  reporter minigene for assessing VEGF exon 6A splicing Figure 1
Splicing of endogenous VEGF gene and design of GFP 
reporter minigene for assessing VEGF exon 6A splic-
ing. A. Exon utilization in VEGF165 and VEGF189. Both 
VEGF165 and VEGF189 use exons 1 through 5 plus exon 7 
and 8. The mRNA for VEGF189 also contains the alterna-
tively spliced exon 6A. B. Design of the GFP reporter mini-
gene for assessment of VEGF exon 6A usage. The minigene 
consists of a GFP gene driven by cytomegalovirus (CMV) 
promoter which is interrupted by a shortened version of 
VEGF intron 5, exon 6A and a shortened version of intron 6. 
Detailed description of the components is given in Methods. 
There are two possible splicing reactions for the transcripts 
of pGFP-E6A. If the splicing pattern is like that in VEGF189, 
exon 6A is included so as to interrupt the GFP reading 
frame. If the splicing pattern is similar to that in VEGF165, 
exon 6A is excluded and a complete GFP open reading frame 
is generated giving rise to active GFP protein. The arrows 
indicated the position of primers used for amplification of 
spliced mRNA products.
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frame will be interrupted. Conversely, if the pGFP-E6A
transcript follows the VEGF165 splicing pathway, VEGF
exon 6A is excluded and an intact open reading frame for
GFP is obtained with expression of GFP.
Human embryonic kidney 293 cells (HEK293) were used
to assess splicing of the transfected reporter minigene. The
HEK293 cells were transfected with pGFP-E6A and/or
control plasmids expressing just GFP or RFP and the cells
were subsequently examined by fluorescent microscopy
and flow cytometry (Figure 2). After transfection of the
pGFP and pRFP control plasmids, cells of the expected
color were observed by fluorescent microscopy and when
both plasmids were cotransfected, cells with fluorescence
in red and green channels were observed (Figure 2A).
When the pGFP-E6A plasmid was transfected, green fluo-
rescence was observed by microscopy comparable in
intensity to that seen in cells transfected with pGFP.
Cotransfection with pRFP allowed comparable signal to
be seen in both channels suggesting the pGFP-E6A plas-
mid is efficiently spliced to form the intact open reading
frame of GFP, i.e., it was spliced in the same pattern as
inVEGF165. Flow cytometry was used to quantify the flu-
orescence (Figure 2B). The frequency of GFP, RFP double
positive cells was similar (19%) when the pGFP control
plasmid was contransfected with pRFP as when pGFP-E6A
Verification of splicing pattern ofrom transfected pGFP-E6A reporter minigene Figure 2
Verification of splicing pattern ofrom transfected pGFP-E6A reporter minigene. A. HEK293 cells were transfected 
with combinations of pGFP, pRFP and pGFP-E6A as shown above each pair of photographs. After 48 hr, the fluorescence was 
assessed in the green and red channels. All photographs taken with the same exposure to compare intensities. B. Flow cytom-
etry of HEK293 cells 48 hr post transfection assessing fluorescent intensity in red and green channels. The percentages of fluo-
rescent cells are shown in each quadrant.
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was contransfected with pRFP (21%). We conclude that
the VEGF 165 splicing pathway is predominant in this cell
type as reflected in the splicing of both the endogenous
VEGF gene and the transfected reporter minigene.
To confirm that the pGFP-E6A plasmid faithfully reports
the splicing pattern of the endogenous VEGF gene, the
splicing of endogenous VEGF gene and transfected pGFP-
E6A was compared in HEK293 and the BT474 cell line.
BT474 cells have been reported to express a high level of
VEGF189 [31]. In BT474, the average rate of endogenous
VEGF E6A inclusion in 3 independent experiments was
15.2 ± 1.3% compared with 4.7 ± 0.3% in HEK293 cells
(Figure 3). For pGFP-E6A plasmid transfected cells, the
average E6A inclusion rate in BT474 was 19.1 ± 0.5%
compared with 5.3 ± 0.8% in HEK293 cells (Figure 3).
Thus, exon 6A utilization for endogenous VEGF gene and
the reporter genes in different cells types were compara-
ble.
Mapping of the cis-acting Elements with Exon 6A
We performed scanning mutagenesis across the exon 6A.
Nine nucleotide long deletion mutations were made
across exon 6A in the context of pGFP-E6A to locate
potential splicing silencers (i.e., sequences whose deletion
would result in enhanced utilization of exon 6A, Figure
4A). To identify putative exonic splicing enhancers (i.e.,
sequences whose deletion would result in reduced usage
of exon 6A), the same deletions were introduced into the
context of pGFP-E6A+, a similar plasmid with enhanced
exon 6A branch point, splice acceptor and splice donor
[30]. The first three nucleotides at the 5' end and the last
six nucleotide at the 3' end were not mutated to avoid the
disruption of normal splice site recognition. In the pro-
duction of VEGF exon 6A plasmids and deletion mutants
we also discovered a naturally occurring mutation in exon
6A that would mutate amino acid 133 of VEGF189 from
arginine to leucine (CGG to CTA). Interestingly this muta-
tion would disrupt the splice acceptor for VEGF183 [14].
This mutation was found to be present in 3 out of 40 alle-
les sequenced from blood bank samples. When this muta-
tion was introduced into the context of the pGFP-E6A
reporter plasmid, it had no impact on the usage of the
exon 6A in HEK293 cells (not shown).
After transfection of the deletion mutations of pGFP-E6A
into HEK293 cells, the splicing pattern was assessed by
RT-PCR (Figure 4B). In the context of pGFP-E6A, Δ3 con-
sisting of a deletion of nucleotides 22 to 30 of exon 6A,
increased the inclusion of exon 6A in the mRNA by 31.7
± 2.4 % over the native exon of transcripts contained exon
6A compared to of 6.8 ± 1.8% for the unmutated control,
difference of 24.8 ± 2.1% (Figure 4D) or 4.7 ± 0.4 fold
increase. The other deletions mutations had lesser impact
on the inclusion of exon 6A. In the context of the pGFP-
E6A+ plasmid, none of the deletion mutations resulted in
enhanced exclusion of exon 6A as might be expected from
deletion of an exonic splicing enhancer. But again, Δ3 pro-
moted the maximum inclusion of exon 6A (Figure 4C), as
it did in the context of the pGFP-E6A plasmid (see Figure
4D for quantitative data). This suggests the presence of an
exonic splicing silencer in nucleotides 22-30 of exon 6A.
To support the experimental evidence for the existence of
a possible cis-acting splicing silencing element, we
screened the exon 6A sequence to find exonic splicing
silencers (ESS) using a web based search utility http://
genes.mit.edu/fas-ess/[32]. This program predicted 4 pos-
sible ESS in the sequence of exon 6A. One of these com-
prised the sequence AAGGGG within the 9 nucleotide
deletion (AAAGGGGCA) identified experimentally.
Mutagenesis of the Proposed Exonic Splicing Silencer
To map critical elements within the putative ESS, we cre-
ated a series of single nucleotide tranversions mutants
Splicing profile of endogenous VEGF gene andtransfected  with pGFP-E6A plasmids in HEK293 and BT474 cells Figure 3
Splicing profile of endogenous VEGF gene andtrans-
fected with pGFP-E6A plasmids in HEK293 and 
BT474 cells. A. mRNA for endogenous human VEGF iso-
forms were amplified using specific primers on mRNA 
extracted from of HEK293 and BT474 cells. The expected 
sizes of the products are indicated on the right. B. HEK293 
and BT474 cells in triplicate were transfected with pGFP-
E6A. After 48 hr, total RNA were assessed using RT-PCR. 
The anticipated positions of the products from the splicing 
events with inclusion or exclusion of exon 6A are indicated 
by arrows. C. Comparison of Exon 6A inclusion rate for 
endogenous and transfected reporter minigene between 
HEK293 cells and BT474 cells. The average ± standard error 
for three experiments is shown.
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spanning the polypurine sequence (AAAGGGG) within
the Δ3 deletion. These changes were introduced in the
context of the pGFP-E6A minigene and the mutant
reporter minigenes were transfected into HEK293 cells
and the impact on splicing was assessed by RT-PCR. As
observed previously, the wild type exon 6A sequence
resulted in the exclusion of exon 6A but point mutations
in the putative ESS resulted in increased inclusion of exon
6A. The point mutant G26C provided the maximum
inclusion of exon6A (26 ± 2.6%) with the flanking muta-
tions G25C and G27C providing a lesser inclusion level
(13 ± 1.7% and 11 ± 0.6% respectively) but still greater
than for the wildtype sequence (Figure 5).
The wildtype and G26C mutant sequence that promoted
inclusion of exon 6A were compared with a web utility
that predicts splicing factors that interact with specific
sequences in pre-mRNA http://www.ebi.ac.uk/asd/[33].
The utility predicted sites where three heterogeneous
nuclear riboncleoproteins (hnRNP), hnRNP F, hnRNP H,
nhRNP U may interact with the nucleotides in the puta-
tive ESS [34]. Of these, the binding of hnRNP H was pre-
dicted to be eliminated by the G26C mutation.
In Vivo Studies of Splicing with Deletion Mutants of 
Putative Exonic Splicing Silencer
Because this putative ESS was initially identified in vitro in
a transformed cell line, we next confirmed the data in vivo,
initially in the context of the pGFP-E6A reporter miniplas-
mid. High volume tail vein injection of naked plasmids
was used to obtain hepatic expression of the minigene. A
luciferase plasmid was coinjected to ensure that the pGFP-
E6A plasmid had efficiently been delivered. RT-PCR anal-
ysis of the liver RNA showed an overall expression pattern
Effect of deletions in exon 6A on splicing activity of pGFP-E6A minigenes Figure 4
Effect of deletions in exon 6A on splicing activity of pGFP-E6A minigenes. A. Sequence of full-length human VEGF 
exon 6A with the splice donor and acceptor sites indicated with black arrows. The naturally occurring mutation (GG mutated 
to TA) in exon 6A overlapping with the splice donor for VEGF183 is shown below the sequence row. Seven sequential nine 
nucleotide long sequential deletions were made across VEGF exon 6A in the context of pGFP-E6A and pGFP-E6A+ plasmids, 
excluding the sequences near splice donor and splice acceptor sites. The putative exonic splicing silencer is shown above the 
sequence (underlined). B. RT-PCR analysis of splicing pattern 48 hr following transfection of pGFP-E6A deletion plasmids into 
HEK293 cells. The anticipated positions of the products from the splicing events with inclusion or exclusion of exon 6A are 
indicated by arrows. C. RT-PCR analysis of splicing pattern 48 hr following transfection of pGFP-E6A+ deletion plasmids into 
HEK293 cell. The anticipated positions of the products for the splicing events with inclusion or exclusion of exon 6A are indi-
cated by arrows. MW = lane with molecular weight markers. D. The percentage of exon 6A inclusion was calculated following 
densitometry of the gel as [E6A included band/(E6A included band + E6A excluded band)] ×100 followed by subtraction of 
wildtype background. Experiments were repeated 4 times in the context of pGFP-E6A (closed symbols) or three time in the 
context of pGFP-E6A+ (open symbols) and the average % inclusion from repeated transfections and the standard error are 
shown.
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that mimicked that seen in vitro (Figure 6A). For the posi-
tive control, pGFP-E6A+, 92 ± 4% of the mRNA had exon
6A included as in VEGF189. For the livers from pGFP-E6A
injected mice, only 11 ± 2% of the mRNA had exon 6A
included (Figure 6B). The introduction of the Δ3 muta-
tion, deleting the putative exonic splicing silencer,
resulted in 29 ± 6% of the mRNA having exon 6A included
(p < 0.01 compared to pGFP-E6A group). Thus, the
impact of the Δ3 mutation in vivo was 2.7 ± 0.3 fold
enhancement of the usage of exon 6A, which is slightly
less than the impact of the same mutation in vitro. We con-
clude that the putative exonic splicing silencer works sim-
ilarly in the liver as it does in vitro, at least in the context
of the minigene reporter plasmid.
Although this putative exonic splicing suppressor works
well in the context of the minigene, there are differences
between the minigene and the actual genomic context of
the VEGF gene. The minigene contains incomplete VEGF
introns 5 and 6 and, additionally, the 5' and 3' exons are
derived from GFP rather than comprising VEGF exons 5
and 7. In order to confirm our results in the context of
human genomic VEGF gene, the Δ3 deletion was intro-
duced into the VEGF-All gene which consists of cDNA
exons 1-5 followed by the genomic configuration of exons
6 to 8. The VEGF-AllE6A.Δ3 gene was used to make a rep-
lication deficient adenovirus vector AdVEGF-AllE6A.Δ3.
This vector and the control vectors AdVEGF-All with
native splicing signals and AdVEGF-All6A+ with enhanced
exon 6A recognition were injected into mice by the tail
vein with RT-PCR assessment of splicing pattern in liver
after 2 days (Figure 7 tent with the expected splicing pat-
tern for VEGF189. For AdVEGF-All, with the native VEGF
sequences except intron 1-4, only 10 ± 3% of the RT-PCR
product was consistent with the expected size for
VEGF189. The introduction of the Δ3 mutation, deleting
the putative exonic splicing silencer, resulted in 21 ± 4%
of the RT-PCR product was consistent with the expected
size for VEGF189 (p < 0.05 compared to AdVEGF-All
group). These results confirm that the putative exonic
splicing silencer is functional in the mouse liver in the
context of the VEGF gene.
Discussion
Assessment of the efficacy of therapeutic gene transfer
with different isoforms of VEGF has demonstrated that
optimum angiogenesis is achieved following delivery of a
combination of VEGF isoforms with a preponderance of
VEGF189 [28,30]. The optimal design of such vectors was
dependent on an understanding of the cis and trans factors
that dictate cell specific splicing of VEGF gene primary
transcripts. However, such vectors must produce
VEGF189 in tissues, such as liver, where the usual splicing
pattern of the endogenous gene does not result in expres-
sion of VEGF189. In this study, we have developed a read-
ily monitored reporter minigene construct that allows us
to monitor the usage of the VEGF exon 6A, the exon used
exclusively in VEGF189. The reporter minigene construct
Effect of point mutations within the VEGF exon 6A putative exonic splicing silencer Figure 5
Effect of point mutations within the VEGF exon 6A putative exonic splicing silencer. A. Partial sequence of VEGF 
exon 6A with splice donor site and putative ESS sequence (underlined). The seven mutant versions with purine to pyrimidine 
transversions are shown. B. RT-PCR analysis of splicing pattern 48 hr following transfection of pGFP-E6A single nucleotide 
substitution plasmids into HEK293 cell. The anticipated positions of the products for the splicing events with inclusion or 
exclusion of exon 6A are indicated by arrows. MW = lane with molecular weight markers. The exon inclusion percentage was 
calculated following densitometry of the gel as [E6A included band/(E6A included band + E6A excluded band)] × 100. Experi-
ment was repeated 3 times and the average % inclusion from 3 replicate transfections and the standard error was shown.
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allowed identification of a putative exonic splicing
silencer of exon 6A usage consisting of an oligopurine
tract within exon 6A. This sequence was functional in sup-
pressing exon 6A usage both in vitro and in vivo and was
effective when introduced back into the native context of
VEGF gene and assessed in vivo.
Control of Splicing of the VEGF Gene
While it is clear that the different VEGF isoforms have dif-
ferent biological properties, there is only a rudimentary
understanding of the determinants of VEGF gene splicing.
However, the pattern of expression suggests complex reg-
ulation of splicing with all isoforms being expressed in a
tissue, cell and developmentally controlled manner. The
best described splicing determinant is the expression of
the inhibitory isoform of VEGF165b for which the role of
splicing factors has been assessed in cotransfection exper-
iments [35]. The data suggest that the choice of the splice
acceptor site in exon 8 is determined in part by the activity
of the trans  splicing factors 9G8 (SFRS7) and SR-55
(SFRS6). Also, the SLM-2 RNA processing protein has
been shown by antisense technology to be involved with
the utilization of VEGF exon 7 and expression of VEGF165
in glomerular epithelial cells [36]. Another important
recent finding is the identification of factors that influence
the expression of pro- and anti-angiogenic forms of VEGF
based on exon 8 usage. Growth factors such as TGFβ1
result in phosphorylation of cis splicing factors such as
SRp55 which interacts direct with the pre-RNA and influ-
ences exon 8 selection [12]. At the translational level,
VEGF was also been studied for the possible regulators.
Eukaryotic initiation factor 4E (elF-4E) enhanced VEGF
expression through translational regulation rather than
transcriptional regulation in cells overexpressing elF-4E
[37]. Prior to the current study there is no information on
the mechanism by which exon 6A is selected. The lung
and heart are the principal tissues that express this isoform
but the critical cell-specific factors that dictate exon 6A rec-
ognition in these cells are unknown. If exon 6A, used in
In vivo effects of deletion of exon 6A nucleotides 22-30 on  splicing in reporter construct Figure 6
In vivo effects of deletion of exon 6A nucleotides 22-
30 on splicing in reporter construct. Mice (n = 3/group) 
were injected by high volume tail vein method with 1.6 ml of 
PBS containing 100 μg of plasmid. After 2 days, mice were 
sacrificed and liver was recovered and used for RNA prepa-
ration. Total RNA was treated with DNaseI to avoid the con-
tamination by genomic DNA A. One-step RT-PCR analysis of 
splicing pattern. Each lane represents RT-PCR product from a 
different mouse. The anticipated positions of the products for 
the splicing events with inclusion or exclusion of exon 6A are 
indicated by arrows. MW = lane with molecular weight mark-
ers. B. The exon 6A inclusion percentage was calculated 
from densitometric scan of gels as described for Figure 4, and 
the mean ± standard deviation is plotted for each group.
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the formation of the mRNA for VEGF189, is a typical alter-
natively spliced exon, there are likely cis sequences in or
around the exon that are recognized by cell specific factors
and regulate its usage. These could either promote exon
6A usage (i.e., exonic specific enhancers) or suppress its
usage (exonic specific silencers).
To identify the cis determinants of exon 6A usage, we used
a reporter minigene system. Minigene reporter systems are
commonly used to facilitate the study of alternative splic-
ing where only one or a few exons and their flanking
regions are cloned in a heterologous reporter gene con-
text. This approach has been used in the past to assess
splicing determinants in microtubule-associated protein
tau exon 10, polypyrimidine tract binding protein exon
11, FGFR2 exon IIIb and IIIc, CD45 and other genes [38-
44]. In this context of the minigene, exon 6A was effi-
ciently excised, consistent with the predominance of
VEGF165 over VEGF189 in most tissues and cell lines
[18]. We also identified a portion of exon 6A that upon
deletion lead to enhanced usage of exon 6A. The nucle-
otide sequence (AAAGGGGCA) overlaps with the known
binding sites for three hnRNP proteins, hnRNP F, hnRNP
H and hnRNP U. These and other hnRNPs are known to
bind to mRNA sequences and in some contexts suppress
the usage of exons to which they bind [45-49]. In particu-
lar, hnRNP H has been shown to bind to a exonic splicing
silencer and control alternate splicing of the rat β-tropo-
myosin gene [47]. It is also involved as a negative regula-
tor of splicing in genes such as Rous Sarcoma virus
genome, bcl-x and FGFR2 genes [50-52]. The individual
nucleotides of the putative exonic splicing silencer were
mutated and the G26 was identified as being the most crit-
ical residues for suppression of exon 6A usage. By bioin-
formatic analysis, this was most consistent with the ESS
being a target for hnRNP F or hnRNP H [33].
The use of a reporter minigene system in a partially trans-
formed cells line has at least two limitations. The first is
that splicing happens in an artificial context without the
other VEGF introns and exons which are normally spliced
sequentially and may compete for general and alternate
splicing factors. The second is that the HEK293 cell line is
partially transformed by the adenovirus E1 region; it is
known that transformed cell lines sometimes have aber-
rant splicing pathways and that viral proteins have specific
effects on splicing [53,54]. Therefore the ESS deletion
mutant was assessed by in vivo gene transfer which results
in expression primarily in hepatocytes [55,56]. In the
minigene context in vivo, the deletion of the ESS had the
expected effect of increasing VEGF exon 6A utilization.
Therefore the deletion mutation was also reintroduced
into the VEGF gene with the alternatively spliced exons in
the native context [28]. In this context the deletion muta-
tion that removed the ESS also was effective in promoting
the utilization of exon 6A for expression of VEGF189.
Use of the minigene to identify a cis-element in VEGF
exon 6A has some potential limitations. For example, the
expression of minigene is not permanent so it is difficult
to follow the changes in splicing events occurred during a
chronic disease progression such as cancer. Also, for the
GFP-minigene, differences or changes in fluorescence may
not always reflect differences in splicing due to differences
in transcription of the fluorescent reporter. Another limi-
tation in our study is although we introduced the muta-
tion of ESS back in human VEGF genomic context and
showed its effect in vivo, the VEGF genomic sequence in
this minigene lacks intron 1-4, which is still not the com-
plete native VEGF gene. Furthermore, though our in vitro
and in vivo study clearly showed the existence of ESS in
VEGF exon 6A, it's also important to prove it in tissues
known to express VEGF189 like the lung or the heart in
future study in vivo.
By use of a minigene expressing a GFP reporter gene, it is
possible to follow the splicing of a minigene in real time.
For example, monitoring changes in splicing patterns dur-
ing development as well as in the progression of disease
such as cancer would be possible in transgenic mouse
models. Changes in VEGF splicing have been described in
embryogenic development and cancer progres-
sion[17,19,24,25,27]. There is substantial evidence that
alternative splicing of the VEGF gene involved in angio-
genesis can regulate the angiogenic drive in tumors, and
that tumor-mediated alterations in splicing may be part of
the angiogenic switch. Furthermore, drugs, such as
TG003, a kinase inhibitor that targets Clk1 (Cdc2-like
kinase 1) and Clk4, might be used to regulate the splicing
of genes in vitro or/and in vivo [57]. The VEGF splicing
reporters described here would thus be applicable for
studies in these circumstances. Further development of
additional reporter constructs based on the modular
nature of the construct described in this paper will be use-
ful to study of alternative splicing events in cell culture
and transgenic animal models.
Conclusion
Different isoforms of VEGF are generated by tissue specific
alternate splicing and the VEGF165 and VEGF 189 iso-
forms differ by the presence or absence of exon 6A. In this
study, a reporter minigene was used to identify cis
sequences that regulate utilization of VEGF exon 6A and
dictate the relative expression levels of VEGF isoforms.
This sequence acted as a exonic splicing silencer in the
context of the minigene and the native context of VEGF
both in vitro and in vivo.BMC Molecular Biology 2009, 10:103 http://www.biomedcentral.com/1471-2199/10/103
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Methods
Plasmid Construction
Plasmid pAcGFP1-C1 expressing green fluorescent pro-
tein (GFP) and pAsRed2-C1 expressing red fluorescent
protein (RFP) were from Clontech (Mountain View, CA).
The vector pGFP-E6A, based on pAcGFP1-C1, is a GFP
reporter minigene designed such that the splicing event in
VEGF165 gives an active GFP protein. The VEGF exon 6A
and shortened forms of its flanking introns were inserted
between nucleotides 285 and 286 of the green fluorescent
protein (GFP) coding sequence. The gene was assembled
in three pieces. Overlap PCR was used to fuse the 5' end of
the GFP gene to human VEGF intron 5 nucleotides 1 -
291. A separate PCR reaction amplified human VEGF gene
from intron 5 nucleotide 1539 (274 basepairs (bp) before
the splice acceptor of exon 6A), to intron 6 nucleotide 238
(with respect to VEGF189 splice donor). This domain
includes exon 6A. In a third reaction, overlap PCR was
used to fuse the 3' end of GFP gene to the 3' end of intron
6 of the human VEGF gene (starting 366 bp before the
splice acceptor of exon 7). The length of shortened intron
5 and intron 6 were 565 bp and 604 bp respectively. The
three parts were assembled and the sequence was verified
(Figure 1B).
The pGFP-E6A+ plasmid was similar to pGFP-E6A except
for introduction of mutations at the intron 5 branch point
(from ACCTTAC to cCCTgAg) and the exon 6A splice
donor (from TTTTTATTTCCAG/AA to TTTTTcTTTCCAG/
AA) and exon 6A splice acceptor (from GT/GTACGT to
GT/GTAaGT) to enhance usage of exon 6A[30]. Deletion
mutants of pGFP-E6A and pGFP-E6A+ as well as point
mutants of pGFP-E6A were also generated using Quik-
Change II XL Site-Directed Mutagenesis kit (Stratagene, La
Jolla, CA) following the manufacturer's protocol. All
mutant constructs were sequenced to confirm the pres-
ence of mutations.
Cell Culture, Transfection and RNA Extraction
HEK293 (Human embryonic kidney cells, ATCC Manas-
sas, VA) cells were maintained in DMEM medium at 37°C
in a humidified atmosphere of 5% CO2. Cells (~106) were
transfected (Polyfect, Qiagen, Valencia, CA) with 4 μg of
plasmid and harvested after 48 hr. Total RNA was pre-
pared using RNeasy Mini kit (Qiagen) following the man-
ufacturer's protocol.
Reverse Transcription-PCR (RT-PCR)
RT-PCR was carried out with a one-step RT-PCR kit (Qia-
gen) at 50°C for 30 min, 95°C for 15 min, followed by 35
cycles of 94°C for 30 sec, 52°C for 30 sec, 72°C for 30 sec
using the forward primer (5'-GCCCATCCTGATCGAGCT-
GAAT) and reverse primer (5'-GTGGGCGTTGTAGTTG-
TACTCCATCTT 3) which can specifically anneal to the 3'
and 5' fragments of GFP yielding a product of 481 bp if
exon 6A is utilized and 409 bp if exon 6A is excluded. To
amplify mRNA expressed by the endogenous human
VEGF gene in HEK293 and BT474 cell lines, RT-PCR prim-
ers consisted of the forward primer (5'-GGCCTGGAGT-
GTGTGCCCACTG) and reverse primer (5'-
CGGCAGCGTGGTTTCTGTATCGA) which give a 477 bp
product for VEGF 189, 405 bp for VEGF165 and 273 bp
for VEGF121. The PCR products were separated on a 2%
TBE-agarose gel, stained with ethidium bromide, and
photographed on a UV transilluminator. The sequence of
the RT-PCR products was confirmed by excision of the
bands from the gel and DNA purification by QIAquick Gel
Purification kit (Qiagen) and dideoxy sequencing. Splic-
ing efficiency was calculated as the ratio between the
intensity of the band including exon 6A divided by the
sum of the intensities for the two bands including and
excluding exon 6A using MetaMorph software (Universal
Imaging Corporation, Downingtown, PA).
Fluorescent Microscopy and Flow Cytometric Analysis
Cells were transfected as described above and after 48 hr
were harvested using trypsin-ethylenedimane tetraacetic
acid. The cells were washed twice with phosphate buffered
saline (PBS), and suspended in 200 μl 2% paraformalde-
hyde, mixed and transferred to flow cytometry (FACS)
tubes and analyzed immediately on a FACSCalibur (BD
biosciences, Pharmingen). Flow cytometric data was ana-
lyzed using FlowJo software. A duplicate set of cells was
analyzed by fluorescent microscopy using Olympus IX70
(Olympus Microsystems America, Redwood City, CA).
High Volume Tail Vein Injection of Plasmids
All experiments in mice were performed under protocols
approved by Institutional Animal Care and Use Commit-
tee. Male BALB/c mice (n = 3/group) received 100 μg plas-
mid DNA (pGFP-E6A, pGFP-E6A+, pGFP-E6Δ3) mixed
with 10 μg pCMV-Luciferase diluted in PBS by tail vein
injection. Mice were rapidly injected with DNA in a large
volume of saline (1.6 ml) within 5 sec using a 26-gauge
needle. After 48 hr, the liver of each mouse was dissected
at the anterior lower part of left lobe exclusively to exclude
spatial variability, snap-frozen in dry ice and stored at -
80°C until further processing. Luciferase assay of liver
homogenate was used to verify the success of the high vol-
ume tail vein injection method. For mouse tissue samples,
the RNeasy Midi kit (Qiagen) was used to isolate the total
RNA. The RNA samples were then treated with DNase I
(Invitrogen, Carlsbad, CA) to remove genomic DNA con-
taminants and then subjected to RT-PCR as described
above.
Adenovirus Vector Construction
VEGF-All is a hybrid cDNA/genomic gene comprising the
human VEGF cDNA exons 1-5 followed by the genomic
configuration of exons 6 to 8 with the exception of anBMC Molecular Biology 2009, 10:103 http://www.biomedcentral.com/1471-2199/10/103
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internal deletion to reduce the size of intron 7 from 2425
to 721 bp. AdVEGF-All is an E1- E3- adenovirus (Ad) vec-
tor expressing VEGF-All from the cytomegalovirus imme-
diate early promoter/enhancer (CMV) [30]. AdVEGF-
All6A+ is similar to AdVEGF-All except for three muta-
tions in the splicing signals around exon 6A that promote
inclusion of exon6A in the mRNA. The AdVEGF-
AllE6A.Δ3 is identical to AdVEGF-All except the nucle-
otides 22-30 of exon 6A were deleted. A similar Ad vector
with LacZ transgene (AdLacZ) was used as a negative con-
trol. Vectors were propagated on HEK293 cells and puri-
fied by two cesium chloride density gradients. Dosing was
carried out based on particle units (pu).
In Vivo Splicing of VEGF Exon 6A Expressed from 
Adenoviral Vectors
For  in vivo experiments, 6 to 8 wk BALB/c mice were
injected through the tail vein with 1010 pu of AdVEGF-All,
AdVEGF-All6A+ or AdVEGF-AllE6A.Δ3 in 100 μl PBS.
After 48 hr, the liver of each mouse was collected for RNA
isolation and analysis by RT-PCR with forward primer
located in exon 3 and exon 4 (5'-ATCACCATGCAGAT-
TATGCGGATC) and a reverse primer (5'-GTGGTAT-
GGCTGATTATGATCAG) located in the polyA site of the
CMV based plsmid so that only the splicing variants of the
adenovirus-minigene could be amplified and the endog-
enous VEGF will not be picked up.
Statistical Analysis
To quantitatively assess differences in splicing patterns
among different groups, digital photographs of stained
gels were quantified by Metamorph software adjusting for
background in each lane. The percentage of the total
intensity attributable to VEGF189 was compared for dif-
ferent groups by two tailed Student's t test.
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